When and how should continuous veno‑venous hemodialysis (CVVHD) be used in critically ill patients with acute kidney injury, including indications, prescription settings, and anticoagulation recommendations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

CVVHD in Critically Ill Patients with Acute Kidney Injury

In hemodynamically unstable critically ill patients with AKI, continuous veno-venous hemodialysis (CVVHD) is the physiologically preferred modality over intermittent hemodialysis, though RCTs have not demonstrated mortality benefit; prescribe an effluent volume of 20-25 mL/kg/hour with regional citrate anticoagulation as first-line unless contraindicated. 1

Indications for CVVHD

CVVHD should be selected based on patient hemodynamic status and clinical context:

  • Hemodynamic instability: CVVHD is more physiologically appropriate than intermittent hemodialysis in patients requiring vasopressor support 1
  • Elevated intracranial pressure: Both modalities affect intracranial pressure, but intermittent hemodialysis carries higher risk 1
  • Multi-organ support: When patients require ECMO or other extracorporeal life support, continuous RRT is more appropriate given hemodynamic considerations 1

Important caveat: Despite physiologic rationale, RCTs have not demonstrated superior mortality outcomes with continuous versus intermittent RRT. The choice should factor in local expertise, available resources, and personnel training 1.

Prescription Settings

Effluent Dose

Deliver 20-25 mL/kg/hour of effluent volume 1. This represents the standard dose supported by KDIGO 2020 guidelines.

  • Higher prescription volumes may be needed to achieve this delivered dose 1
  • Evidence suggests 35 mL/kg/hour may improve survival compared to 20 mL/kg/hour in critically ill patients 2
  • The goal is achieving adequate electrolyte, acid-base, solute, and fluid balance for each patient 1

Blood Flow Rate

Maintain blood flow at 120-150 mL/min via blood pump 3

Dialysate Flow

Bicarbonate-based dialysate should be delivered at 700-900 mL/hour 3

Vascular Access

Catheter selection and site hierarchy:

  1. First choice: Right internal jugular vein or femoral vein
    • Femoral site is inferior in patients with increased body mass 1
  2. Second choice: Left internal jugular vein
  3. Third choice: Subclavian vein 1

Catheter type:

  • Use uncuffed non-tunneled dialysis catheter of appropriate length and gauge for initiation 1
  • Consider cuffed catheter if prolonged RRT is expected 1

Anticoagulation Strategy

Regional citrate anticoagulation is the recommended first-line approach for CVVHD in patients without contraindications 1. This recommendation from 2012 KDIGO guidelines remains supported by current evidence.

Citrate Anticoagulation Monitoring

When using citrate-calcium anticoagulation:

  • Target post-filter ionized calcium: approximately 1.60 (1.40-1.80) mg/dL 4
  • Monitor systemic ionized calcium: maintain around 4.35 (4.10-4.60) mg/dL 4
  • Watch for severe hypocalcemia (systemic ionized calcium <3.6 mg/dL), which occurs in approximately 4% of procedures 4

Critical consideration in hyponatremia: Standard citrate solutions provide substantial sodium load (mean 1754 mmol daily), which can cause excessively rapid sodium correction (>8 mmol/L/24h) in nearly half of hyponatremic patients 5. Monitor plasma sodium frequently in this population.

Alternative Anticoagulation

If citrate is contraindicated, anticoagulation type should be selected based on local resources and personnel expertise 1.

Filter Management

  • Expected median filter patency: approximately 24-28 hours 4
  • Monitor transmembrane pressure, urea sieving coefficient, and filtration fraction to assess filter function 2
  • Use synthetic membranes over cellulose-based membranes 2

Factors associated with shorter filter life:

  • Active cancer disease
  • Lower citrate dosing
  • Lower INR
  • Higher platelet counts 4

Transition and Discontinuation

Transition from CVVHD to intermittent hemodialysis when:

  • Vasopressor support has been discontinued
  • Intracranial hypertension has resolved
  • Positive fluid balance can be controlled by intermittent hemodialysis 1

Discontinue RRT when:

  • Kidney function has recovered
  • RRT becomes inconsistent with shared care goals 1

Common Pitfalls

  1. Underdosing: Prescribe higher than 20-25 mL/kg/hour to ensure this dose is actually delivered 1
  2. Rapid sodium correction: In hyponatremic patients on citrate anticoagulation, the sodium load from trisodium citrate can cause dangerously rapid correction 5
  3. Inadequate monitoring: Citrate anticoagulation requires frequent monitoring of systemic and post-filter ionized calcium 4
  4. Premature transition: Don't switch to intermittent hemodialysis while patients remain hemodynamically unstable 1

References

Related Questions

When should continuous veno‑venous hemodialysis (CVVHD) be initiated in a hemodynamically unstable ICU patient with acute kidney injury, and what are the recommended blood flow, dialysate and replacement fluid rates, and anticoagulation strategy?
Which diseases can cause clotting of the continuous venovenous hemodialysis (CVVHD) circuit?
What is the appropriate evaluation and initial management for acute kidney injury?
What are the criteria for staging acute kidney injury (AKI) and the recommended management for each stage?
What is the correct medical term for acute kidney injury?
Can Adderall (mixed amphetamine salts) be taken together with Imodium (loperamide)?
Could diabetes insipidus (DI) be responsible for my severe watery diarrhea and near‑syncope after ingesting an entire bottle of magnesium citrate?
What are the D‑zone variations observed in clindamycin susceptibility testing for skin infections?
What are the most common causes of infertility in an otherwise healthy 31‑year‑old woman with a two‑year history of inability to conceive, given that hysterosalpingogram (HSG), pelvic ultrasound, routine blood work, urine testing, and partner sperm analysis are all normal?
What is the appropriate management for low‑normal potassium measured two days after a magnesium‑citrate–induced osmotic diarrhea?
How many hours per day is continuous venovenous hemodialysis (CVVHD) performed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.